COPD Breakthrough: The Ensifentrine Revolution │ PHARMACOLOGY

Update: The FDA has approved ensifentrine (Ohtuvayre; Verona Pharma) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients (www.veronapharma.com/news/ver.... Discover how it works to alleviate the symptoms of COPD, providing a beacon of hope for millions around the world grappling with this respiratory condition. In this video, we’ll explore the science behind ensifentrine, its mechanism of action, and the promising results it has shown in clinical trials.
Disclaimer: This CZcams video is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. Information on this video should not be considered as a substitute for advice from a healthcare professional. The statements made about specific products are not to diagnose, treat, cure, or prevent disease.
References:
1. Gan Q, Wu Y, Su X, et al. Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective. Am J Respir Crit Care Med. 2024;209(2):223-224. doi:10.1164/rccm.202307-1143LE
2. Calzetta L, Cazzola M, Rogliani P. Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials. Am J Respir Crit Care Med. 2024;209(2):224-225. doi:10.1164/rccm.202308-1355LE
3. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC
4. Barjaktarevic I, Rheault T, Bengtsson T, et al. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials. Am J Respir Crit Care Med. 2023;207:A5008
#Ensifentrine #COPD #MedicalBreakthrough #HealthcareInnovation